112 related articles for article (PubMed ID: 35926811)
21. CDX2 immunostaining as a gastrointestinal marker: expression in lung carcinomas is a potential pitfall.
Mazziotta RM; Borczuk AC; Powell CA; Mansukhani M
Appl Immunohistochem Mol Morphol; 2005 Mar; 13(1):55-60. PubMed ID: 15722794
[TBL] [Abstract][Full Text] [Related]
22. Unusual staining of immunohistochemical markers PAX8 and CDX2 in breast carcinoma: a potential diagnostic pitfall.
Shen T; Zhao J; Zhao M; Taggart MW; Ramalingam P; Gong Y; Wu Y; Liu H; Zhang J; Resetkova E; Wang WL; Ding Q; Huo L; Yoon E
Hum Pathol; 2022 Jul; 125():35-47. PubMed ID: 35417734
[TBL] [Abstract][Full Text] [Related]
23. Expression of intestine-specific transcription factors, CDX1 and CDX2, in intestinal metaplasia and gastric carcinomas.
Almeida R; Silva E; Santos-Silva F; Silberg DG; Wang J; De Bolós C; David L
J Pathol; 2003 Jan; 199(1):36-40. PubMed ID: 12474224
[TBL] [Abstract][Full Text] [Related]
24. Columnar cell variant of papillary thyroid carcinoma: a study of 10 cases with emphasis on CDX2 expression.
Sujoy V; Pinto A; Nosé V
Thyroid; 2013 Jun; 23(6):714-9. PubMed ID: 23488912
[TBL] [Abstract][Full Text] [Related]
25. Intestinal and pancreatobiliary differentiation in periampullary carcinoma: the role of immunohistochemistry.
Kumari N; Prabha K; Singh RK; Baitha DK; Krishnani N
Hum Pathol; 2013 Oct; 44(10):2213-9. PubMed ID: 23834763
[TBL] [Abstract][Full Text] [Related]
26. Islet 1 (Isl1) expression is a reliable marker for pancreatic endocrine tumors and their metastases.
Schmitt AM; Riniker F; Anlauf M; Schmid S; Soltermann A; Moch H; Heitz PU; Klöppel G; Komminoth P; Perren A
Am J Surg Pathol; 2008 Mar; 32(3):420-5. PubMed ID: 18300808
[TBL] [Abstract][Full Text] [Related]
27. CDX2, cytokeratins 7 and 20 immunoreactivity in rectal adenocarcinoma.
Saad RS; Silverman JF; Khalifa MA; Rowsell C
Appl Immunohistochem Mol Morphol; 2009 May; 17(3):196-201. PubMed ID: 19098678
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical analysis in a morphologic spectrum of urachal epithelial neoplasms: diagnostic implications and pitfalls.
Paner GP; McKenney JK; Barkan GA; Yao JL; Frankel WL; Sebo TJ; Shen SS; Jimenez RE
Am J Surg Pathol; 2011 Jun; 35(6):787-98. PubMed ID: 21572312
[TBL] [Abstract][Full Text] [Related]
29. Aberrant Cdx2 expression in endometrial lesions with squamous differentiation: important role of Cdx2 in squamous morula formation.
Wani Y; Notohara K; Saegusa M; Tsukayama C
Hum Pathol; 2008 Jul; 39(7):1072-9. PubMed ID: 18495206
[TBL] [Abstract][Full Text] [Related]
30. Expression of Cdx2 and hepatocyte antigen in gastric carcinoma: correlation with histologic type and implications for prognosis.
Fan Z; Li J; Dong B; Huang X
Clin Cancer Res; 2005 Sep; 11(17):6162-70. PubMed ID: 16144916
[TBL] [Abstract][Full Text] [Related]
31. Co-expression of CDX2 and MUC2 in gastric carcinomas: correlations with clinico-pathological parameters and prognosis.
Roessler K; Mönig SP; Schneider PM; Hanisch FG; Landsberg S; Thiele J; Hölscher AH; Dienes HP; Baldus SE
World J Gastroenterol; 2005 Jun; 11(21):3182-8. PubMed ID: 15929165
[TBL] [Abstract][Full Text] [Related]
32. The expression of TTF1, CDX2 and ISL1 in 74 poorly differentiated neuroendocrine carcinomas.
Lee H; Fu Z; Koo BH; Sheehan CE; Young GQ; Lin J; Patil DT; Yang Z
Ann Diagn Pathol; 2018 Dec; 37():30-34. PubMed ID: 30236546
[TBL] [Abstract][Full Text] [Related]
33. Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms: delineation of an "intestinal" pathway of carcinogenesis in the pancreas.
Adsay NV; Merati K; Basturk O; Iacobuzio-Donahue C; Levi E; Cheng JD; Sarkar FH; Hruban RH; Klimstra DS
Am J Surg Pathol; 2004 Jul; 28(7):839-48. PubMed ID: 15223952
[TBL] [Abstract][Full Text] [Related]
34. IMP3, NESP55, TTF-1 and CDX2 serve as an immunohistochemical panel in the distinction among small-cell carcinoma, gastrointestinal carcinoid, and pancreatic endocrine tumor metastasized to the liver.
Denby KS; Briones AJ; Bourne PA; Spaulding BO; Lu D; Fischer-Colbrie R; Qu Z; Wang HL; Xu H
Appl Immunohistochem Mol Morphol; 2012 Dec; 20(6):573-9. PubMed ID: 22495359
[TBL] [Abstract][Full Text] [Related]
35. Is CDX2 immunostaining useful for delineating anorectal from penile/vulvar squamous cancer in the setting of squamous cell carcinoma with clinically unknown primary site presenting with histologically confirmed inguinal lymph node metastasis?
Gunia S; Koch S; May M
J Clin Pathol; 2013 Feb; 66(2):109-12. PubMed ID: 23105122
[TBL] [Abstract][Full Text] [Related]
36. CDX2 as a marker of intestinal EC-cells and related well-differentiated endocrine tumors.
La Rosa S; Rigoli E; Uccella S; Chiaravalli AM; Capella C
Virchows Arch; 2004 Sep; 445(3):248-54. PubMed ID: 15517368
[TBL] [Abstract][Full Text] [Related]
37. Aberrant CDX2 expression in hepatocellular carcinomas: an important diagnostic pitfall.
Shah SS; Wu TT; Torbenson MS; Chandan VS
Hum Pathol; 2017 Jun; 64():13-18. PubMed ID: 28089540
[TBL] [Abstract][Full Text] [Related]
38. SATB2 Is Superior to CDX2 in Distinguishing Signet Ring Cell Carcinoma of the Upper Gastrointestinal Tract and Lower Gastrointestinal Tract.
Ma C; Lowenthal BM; Pai RK
Am J Surg Pathol; 2018 Dec; 42(12):1715-1722. PubMed ID: 30212392
[TBL] [Abstract][Full Text] [Related]
39. CD99 and cytokeratin-20 in small-cell and basaloid tumors of the skin.
Nicholson SA; McDermott MB; Swanson PE; Wick MR
Appl Immunohistochem Mol Morphol; 2000 Mar; 8(1):37-41. PubMed ID: 10937047
[TBL] [Abstract][Full Text] [Related]
40. Cdx2 as a marker for neuroendocrine tumors of unknown primary sites.
Erickson LA; Papouchado B; Dimashkieh H; Zhang S; Nakamura N; Lloyd RV
Endocr Pathol; 2004; 15(3):247-52. PubMed ID: 15640551
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
